why choose us

First received: May 22, 2023

Clinical Trial: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Gland

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Brief Summary: To learn if sacituzumab govitecan can help to control salivary gland cancer.

Read more